ac 430

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg kg day.

HM90822 是一种新型合成凋亡蛋白（IAP）拮抗剂，通过蛋白酶体依赖性降解含有BIR2 3结构域的IAPs诱导人胰腺癌细胞凋亡。HM90822 抑制对 HM822 敏感的 Panc-1 和 BxPC-3 细胞中 XIAP 和 cIAP1 2 蛋白的表达，诱导 IAP 泛素化并促进蛋白酶体依赖性 IAP 降解。

Cis-Bac430作用于调节CD8+抗肿瘤细胞从外围移至肿瘤部位，从而增强免疫检查点抑制剂的抗癌效果。

Ac-PAL-AMC is a fluorogenic substrate for the β1i LMP2 subunit of the 20S immunoproteasome. Upon cleavage, 7-amino-4-methylcoumarin (AMC) is released and its fluorescence can be used to quantify the activity of the β1i LMP2 subunit of the 20S immunoproteasome. Ac-PAL-AMC is selective for the immunoproteasome over the constitutive proteasome. AMC displays excitation emission maxima of 351 430 nm, respectively.